Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study

被引:13
|
作者
Rogler, Anja [1 ]
Hoja, Sabine [1 ]
Giedl, Johannes [1 ]
Ekici, Arif B. [2 ]
Wach, Sven [3 ]
Taubert, Helge [3 ]
Goebell, Peter J. [3 ]
Wullich, Bernd [3 ]
Stoeckle, Michael [4 ]
Lehmann, Jan [5 ]
Petsch, Sabrina [6 ]
Hartmann, Arndt [1 ]
Stoehr, Robert [1 ]
机构
[1] Univ Hosp Erlangen, Inst Pathol, D-91054 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Inst Human Genet, D-91054 Erlangen, Germany
[3] Univ Hosp Erlangen, Dept Urol, D-91054 Erlangen, Germany
[4] Univ Hosp Saarland, Clin Urol & Childrens Urol, D-66421 Homburg, Saar, Germany
[5] Urol Practice Pruner Gang, D-24105 Kiel, Germany
[6] Univ Erlangen Nurnberg, Tumour Zentrum, D-91052 Erlangen, Germany
来源
BMC CANCER | 2014年 / 14卷
关键词
MTUS1; ATIP; Bladder cancer; Chromosome 8p deletions; TRANSITIONAL-CELL-CARCINOMA; RECEPTOR-INTERACTING PROTEINS; POOR-PROGNOSIS; PROSTATE-CANCER; URINARY-BLADDER; CHROMOSOME; 8P; CULTURE MODEL; LINES; PROGRESSION; GENES;
D O I
10.1186/1471-2407-14-214
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Seventy percent of all bladder tumours tend to recur and need intensive surveillance, and a subset of tumours progress to muscle-invasive and metastatic disease. However, it is still difficult to find the adequate treatment for every individual patient as it is a very heterogeneous disease and reliable biomarkers are still missing. In our study we searched for new target genes in the critical chromosomal region 8p and investigated the potential tumour suppressor gene candidate MTUS1/ATIP in bladder cancer. Methods: MTUS1 was identified to be the most promising deleted target gene at 8p in aCGH analysis with 19 papillary bladder tumours. A correlation with bladder cancer was further validated using immunohistochemistry of 85 papillary and 236 advanced bladder tumours and in functional experiments. Kaplan-Meier analysis and multivariate Cox-regression addressed overall survival (OS) and disease-specific survival (DSS) as a function of MTUS1/ATIP expression. Bivariate correlations investigated associations between MTUS1/ATIP expression, patient characteristics and histopathology. MTUS1 expression was analysed in cell lines and overexpressed in RT112, where impact on viability, proliferation and migration was measured. Results: MTUS1 protein expression was lost in almost 50% of all papillary and advanced bladder cancers. Survival, however, was only influenced in advanced carcinomas, where loss of MTUS1 was associated with adverse OS and DSS. In this cohort, there was also a significant correlation of MTUS1 expression and histological subtype: positive expression was detected in all micropapillary tumours and aberrant nuclear staining was detected in a subset of plasmocytoid urothelial carcinomas. MTUS1 was expressed in all investigated bladder cell lines and overexpression in RT112 led to significantly decreased viability. Conclusions: MTUS1 is a tumour suppressor gene in cultured bladder cancer cells and in advanced bladder tumours. It might represent one new target gene at chromosome 8p and can be used as an independent prognostic factor for advanced bladder cancer patients. The limitation of the study is the retrospective data analysis. Thus, findings should be validated with a prospective advanced bladder tumour cohort.
引用
收藏
页数:14
相关论文
共 34 条
  • [21] Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression
    Morente, MM
    Piris, MA
    Abraira, V
    Acevedo, A
    Aguilera, B
    Bellas, C
    Fraga, M
    GarciaDelMoral, R
    GomezMarcos, F
    Menarguez, J
    Oliva, H
    SanchezBeato, M
    Montalban, C
    BLOOD, 1997, 90 (06) : 2429 - 2436
  • [22] Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy
    Gonzalez-Roibon, Nilda
    Kim, Jenny J.
    Faraj, Sheila F.
    Chaux, Alcides
    Bezerra, Stephania M.
    Munari, Enrico
    Ellis, Carla
    Sharma, Rajni
    Keizman, Daniel
    Bivalacqua, Trinity J.
    Schoenberg, Mark
    Eisenberger, Mario
    Carducci, Michael
    Netto, George J.
    UROLOGY, 2014, 83 (06) : 1444.e1 - 1444.e6
  • [23] Anti-PD-1 Monotherapy in Advanced Melanoma-Real-World Data from a 77-Month-Long Retrospective Observational Study
    Kuzmanovszki, Daniella
    Kiss, Norbert
    Toth, Bela
    Kerner, Tunde
    Toth, Veronika
    Szakonyi, Jozsef
    Lorincz, Kende
    Harsing, Judit
    Imredi, Eleonora
    Pfund, Alexa
    Szabo, Akos
    Brodszky, Valentin
    Rencz, Fanni
    Hollo, Peter
    BIOMEDICINES, 2022, 10 (07)
  • [24] Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study
    Rubino, Selene
    Kim, Youngchul
    Zhou, Junmin
    Dhilon, Jasreman
    Li, Roger
    Spiess, Philippe
    Poch, Michael
    Manley, Brandon J.
    Pow-Sang, Julio
    Gilbert, Scott
    Sexton, Wade
    Zhang, Jingsong
    WORLD JOURNAL OF UROLOGY, 2021, 39 (05) : 1539 - 1547
  • [25] Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study
    Selene Rubino
    Youngchul Kim
    Junmin Zhou
    Jasreman Dhilon
    Roger Li
    Philippe Spiess
    Michael Poch
    Brandon J. Manley
    Julio Pow-Sang
    Scott Gilbert
    Wade Sexton
    Jingsong Zhang
    World Journal of Urology, 2021, 39 : 1539 - 1547
  • [26] Multiple Gestation as a Risk Factor for SARS-CoV-2-Associated Adverse Maternal Outcome: Data From the COVID-19 Related Obstetric and Neonatal Outcome Study (CRONOS) (Vol 83, pg 1508, 2023)
    Sourouni, Marina
    Germeyer, Ariane
    Feisst, Manuel
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (12) : e42 - e42
  • [27] Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
    Hayato Kawachi
    Motohiro Tamiya
    Akihiro Tamiya
    Seigo Ishii
    Katsuya Hirano
    Hirotaka Matsumoto
    Yasushi Fukuda
    Toshihide Yokoyama
    Ryota Kominami
    Daichi Fujimoto
    Kazutaka Hosoya
    Hidekazu Suzuki
    Tomonori Hirashima
    Masaki Kanazu
    Nobuhiko Sawa
    Junji Uchida
    Mitsunori Morita
    Takeshi Makio
    Satoshi Hara
    Toru Kumagai
    Investigational New Drugs, 2020, 38 : 211 - 218
  • [28] Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
    Kawachi, Hayato
    Tamiya, Motohiro
    Tamiya, Akihiro
    Ishii, Seigo
    Hirano, Katsuya
    Matsumoto, Hirotaka
    Fukuda, Yasushi
    Yokoyama, Toshihide
    Kominami, Ryota
    Fujimoto, Daichi
    Hosoya, Kazutaka
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Kanazu, Masaki
    Sawa, Nobuhiko
    Uchida, Junji
    Morita, Mitsunori
    Makio, Takeshi
    Hara, Satoshi
    Kumagai, Toru
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 211 - 218
  • [29] Normative values of hemoglobinA1c (HbA1c) in non-diabetic pregnancy (24-32 wks gestation); Data from the hyperglycemia and adverse pregnancy outcome (HAPO) study
    Lappin, Terence R.
    Savage, Geraldine A.
    Metzger, Boyd E.
    Lowe, Lynn P.
    Haggan, Sally A.
    Dyer, Alan R.
    DIABETES, 2006, 55 : A217 - A217
  • [30] Hepatitis B virus infection does not affect the clinical outcome of anti-programmed death receptor-1 therapy in advanced solid malignancies Real-world evidence from a retrospective study using propensity score matching
    Zhong, Liting
    Zhong, PinShun
    Liu, Huafeng
    Li, Zelei
    Nie, Qihong
    Peng, Weiwei
    MEDICINE, 2021, 100 (49)